Skip to main content
Premium Trial:

Request an Annual Quote

PSI Creates Materials Repository at Harvard, Plans Knowledgebase for 2007

NEW YORK (GenomeWeb News) - The Protein Structure Initiative, a ten-year project funded by the National Institute of General Medical Studies, said yesterday that it is creating a materials repository at Harvard University's Institute of Proteomics.
The materials repository will house PSI-generated clones and will ship them to researchers for a small fee that covers handling, processing, and shipping. These clones can be used to make specific proteins for studies of their functions and structures.
The PSI materials repository has received $5.4 million in funding for five years and will be directed by Joshua LaBaer.
PSI director John Norvell said the repository will greatly reduce the time researchers currently spend producing clones and will offer a centralized location holding many of the 20,000 clones PSI-participating centers will create every year.
The PSI, which began in 2000, also plans to establish a knowledgebase in 2007, which will house structural information generated by the centers. PSI said it will allow researchers to find "best available" information about the structure and function of every protein and will offer information about each stage of the structure determination process, and information about all solved PSI proteins will be available.
The PSI said it will continue to pursue technology development. So far, PSI said, advances include: the miniaturization of samples needed to grow, purify, and crystallize proteins; robotic systems to handle samples and image crystals; enhanced software to analyze structural data and create high-resolution images; and improved systems for synthesizing proteins. 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.